SAN DIEGO--(BUSINESS WIRE)--Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, M.D., Ph.D., Chief Scientific Officer, will give a presentation entitled “Cow antibodies with long CDR3s: Biology and Applications” on Monday, June 15, at the Next-Generation Antibodies and Protein Analysis: Tools and Technologies of the VIB Conference Series in Gent, Belgium as an invited speaker.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
